Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia.

Goff DC, Leahy L, Berman I, Posever T, Herz L, Leon AC, Johnson SA, Lynch G.

J Clin Psychopharmacol. 2001 Oct;21(5):484-7.

PMID:
11593073
2.

A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.

Goff DC, Lamberti JS, Leon AC, Green MF, Miller AL, Patel J, Manschreck T, Freudenreich O, Johnson SA.

Neuropsychopharmacology. 2008 Feb;33(3):465-72. Epub 2007 May 9.

3.

A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.

Akdede BB, Anil Yağcioğlu AE, Alptekin K, Turgut TI, Tümüklü M, Yazici MK, Jayathilake K, Tunca Z, Göğüş A, Meltzer HY.

J Clin Psychiatry. 2006 Dec;67(12):1912-9.

PMID:
17194269
4.

Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series.

Marenco S, Egan MF, Goldberg TE, Knable MB, McClure RK, Winterer G, Weinberger DR.

Schizophr Res. 2002 Oct 1;57(2-3):221-6.

PMID:
12223253
5.

Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.

Houthoofd SA, Morrens M, Sabbe BG.

Clin Ther. 2008 Sep;30(9):1565-89. doi: 10.1016/j.clinthera.2008.09.014. Review.

PMID:
18840365
6.

Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review.

Sommer IE, Begemann MJ, Temmerman A, Leucht S.

Schizophr Bull. 2012 Sep;38(5):1003-11. doi: 10.1093/schbul/sbr004. Epub 2011 Mar 21. Review.

8.

The effect of galantamine added to clozapine on cognition of five patients with schizophrenia.

Bora E, Veznedaroğlu B, Kayahan B.

Clin Neuropharmacol. 2005 May-Jun;28(3):139-41.

PMID:
15965314
9.

Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial.

Assion HJ, Reinbold H, Lemanski S, Basilowski M, Juckel G.

Pharmacopsychiatry. 2008 Jan;41(1):24-8. doi: 10.1055/s-2007-993209.

PMID:
18203048
11.

Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia--sub-chronic and early postnatal PCP treatment in attentional set-shifting.

Broberg BV, Glenthøj BY, Dias R, Larsen DB, Olsen CK.

Psychopharmacology (Berl). 2009 Nov;206(4):631-40. doi: 10.1007/s00213-009-1540-5. Epub 2009 Apr 24.

PMID:
19390843
12.

A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia.

Goff DC, Henderson DC, Evins AE, Amico E.

Biol Psychiatry. 1999 Feb 15;45(4):512-4.

PMID:
10071726
13.

Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study.

Stryjer R, Strous R, Bar F, Shaked G, Shiloh R, Rozencwaig S, Grupper D, Buchman N, Kotler M, Rabey JM, Weizman A.

Hum Psychopharmacol. 2004 Jul;19(5):343-6.

PMID:
15252826
14.

Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia.

Sharma T, Hughes C, Soni W, Kumari V.

Psychopharmacology (Berl). 2003 Sep;169(3-4):398-403. Epub 2003 Jul 4.

PMID:
12845415
15.

[Cognition, schizophrenia and the effect of antipsychotics].

Stip E.

Encephale. 2006 May-Jun;32(3 Pt 1):341-50. Review. French.

PMID:
16840928
16.

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.

Lane HY, Huang CL, Wu PL, Liu YC, Chang YC, Lin PY, Chen PW, Tsai G.

Biol Psychiatry. 2006 Sep 15;60(6):645-9. Epub 2006 Jun 14.

PMID:
16780811
17.

Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.

Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD.

J Clin Psychopharmacol. 2008 Apr;28(2 Suppl 1):S20-8. doi: 10.1097/JCP.0b013e318169d4ce.

PMID:
18334909
18.

The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study.

Zoccali R, Muscatello MR, Cedro C, Neri P, La Torre D, Spina E, Di Rosa AE, Meduri M.

Int Clin Psychopharmacol. 2004 Mar;19(2):71-6.

PMID:
15076014
19.

A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety.

Anil Yağcioğlu AE, Kivircik Akdede BB, Turgut TI, Tümüklü M, Yazici MK, Alptekin K, Ertuğrul A, Jayathilake K, Göğüş A, Tunca Z, Meltzer HY.

J Clin Psychiatry. 2005 Jan;66(1):63-72.

PMID:
15669890
20.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

Items per page

Supplemental Content

Write to the Help Desk